Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis

NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD

49.38  -0.63 (-1.26%)

Premarket: 48.4 -0.98 (-1.98%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PTCT. PTCT was compared to 572 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. PTCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PTCT has reported negative net income.
PTCT had a negative operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M

1.2 Ratios

With a decent Return On Assets value of -24.60%, PTCT is doing good in the industry, outperforming 73.27% of the companies in the same industry.
Industry RankSector Rank
ROA -24.6%
ROE N/A
ROIC N/A
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

With an excellent Gross Margin value of 92.20%, PTCT belongs to the best of the industry, outperforming 94.16% of the companies in the same industry.
PTCT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for PTCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTCT has been increased compared to 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
PTCT has a worse debt/assets ratio than last year.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -1.24, we must say that PTCT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.24, PTCT perfoms like the industry average, outperforming 57.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.24
ROIC/WACCN/A
WACC9.4%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.10 indicates that PTCT has no problem at all paying its short term obligations.
The Current ratio of PTCT (2.10) is worse than 75.40% of its industry peers.
PTCT has a Quick Ratio of 2.04. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.04, PTCT is doing worse than 74.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.04
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.94%, which is quite impressive.
PTCT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.84%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 28.79% on average per year.
EPS 1Y (TTM)49.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.02%
Revenue 1Y (TTM)12.84%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%0.11%

3.2 Future

PTCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.18% yearly.
The Revenue is expected to grow by 5.31% on average over the next years.
EPS Next Y26.94%
EPS Next 2Y37.6%
EPS Next 3Y19.92%
EPS Next 5Y21.18%
Revenue Next Year-14.97%
Revenue Next 2Y-1.67%
Revenue Next 3Y-2.28%
Revenue Next 5Y5.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

92.74% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 249.08
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as PTCT's earnings are expected to grow with 19.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.6%
EPS Next 3Y19.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PTC THERAPEUTICS INC

NASDAQ:PTCT (2/4/2025, 8:02:57 PM)

Premarket: 48.4 -0.98 (-1.98%)

49.38

-0.63 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners106.12%
Inst Owner Change-0.13%
Ins Owners0.51%
Ins Owner Change4.87%
Market Cap3.81B
Analysts74.29
Price Target58.87 (19.22%)
Short Float %5.63%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.6%
Min EPS beat(2)-18.68%
Max EPS beat(2)5.49%
EPS beat(4)2
Avg EPS beat(4)-38.87%
Min EPS beat(4)-147.48%
Max EPS beat(4)5.49%
EPS beat(8)2
Avg EPS beat(8)-46.34%
EPS beat(12)2
Avg EPS beat(12)-40.42%
EPS beat(16)3
Avg EPS beat(16)-33.26%
Revenue beat(2)1
Avg Revenue beat(2)5.25%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)11.74%
Revenue beat(4)2
Avg Revenue beat(4)6.4%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)21.39%
Revenue beat(8)4
Avg Revenue beat(8)1.64%
Revenue beat(12)7
Avg Revenue beat(12)2.8%
Revenue beat(16)11
Avg Revenue beat(16)4.48%
PT rev (1m)-1.7%
PT rev (3m)43.73%
EPS NQ rev (1m)29%
EPS NQ rev (3m)58.49%
EPS NY rev (1m)1.38%
EPS NY rev (3m)7.58%
Revenue NQ rev (1m)17.68%
Revenue NQ rev (3m)58.59%
Revenue NY rev (1m)1.19%
Revenue NY rev (3m)9.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 249.08
EPS(TTM)-4.1
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS11.68
BVpS-13.67
TBVpS-19.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.2%
FCFM N/A
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
F-Score3
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 112.78
Cap/Depr 5.55%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.04
Altman-Z -1.24
F-Score3
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)26.95%
Cap/Depr(5y)32.93%
Cap/Sales(3y)4.28%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.02%
EPS Next Y26.94%
EPS Next 2Y37.6%
EPS Next 3Y19.92%
EPS Next 5Y21.18%
Revenue 1Y (TTM)12.84%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%0.11%
Revenue Next Year-14.97%
Revenue Next 2Y-1.67%
Revenue Next 3Y-2.28%
Revenue Next 5Y5.31%
EBIT growth 1Y66.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year87.23%
EBIT Next 3Y30.08%
EBIT Next 5YN/A
FCF growth 1Y36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.43%
OCF growth 3YN/A
OCF growth 5YN/A